Board of Directors
Our Board of Directors come from a wide-range of backgrounds to enable us to access a broad knowledge base.
Garry Watts, FCA, MBE, joined the Board of BTG as non-executive Chairman in January 2012. He is Chairman of the Nomination Committee. Garry is Chairman of Spire Healthcare and of Foxtons Group plc. and non-executive director of Coca-Cola Enterprises, Inc, and Stagecoach Group plc.
Until December 2010, he was for seven years CEO of SSL International plc and before that its CFO. Garry is a former partner at KPMG. He was previously an executive director of Celltech plc and of Medeva plc and a non-executive director of Protherics PLC. Other roles have included 17 years as a member of the UK Medicines and Healthcare Products Regulatory Agency Supervisory Board.
Dame Louise Makin
Chief Executive Officer
Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004. She is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust, a Trustee of the Outward Bound Trust and an Honorary Fellow of St. John’s College, Cambridge.
From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.
Chief Financial Officer
Rolf Soderstrom, BA, ACA, joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007.
From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.
Dr. Susan Foden
Susan Foden, MA, DPhil, joined BTG as a non-executive director in March 2015 and is a member of the Remuneration Committee.
Susan has a background in the field of Biotech and Healthcare and holds a number of Non-Executive positions with both public and private companies. She currently holds non-executive roles with BerGenBio AS, Evgen Ltd, and Vectura Group plc, and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Previously Susan has held the positions of Investor Director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and Head of Academic Liaison at Celltech Ltd.
Graham Hetherington joined BTG as a non-executive director and Chair of the Audit Committee in August 2016 and is a Fellow of the Chartered Institute of Management Accountants.
Prior to joining BTG, Graham was Chief Financial Officer of Shire plc from June 2008 to February 2014 and held the same position at Bacardi in 2007 and at Allied Domecq PLC from 1999 to 2005. He brings with him significant finance and industry experience and has a broad knowledge of international finance management and planning, including M&A, audit and risk management.
Giles Kerr, FCA, joined BTG as a non-executive director in October 2007 and is the Company's Senior Independent Director. He is Chairman of the Audit Committee and a member of the Nomination and Remuneration Committees.
Giles is currently the Director of Finance with the University of Oxford, UK. He is also a Director of Quanta Fluid Solutions Ltd, Isis Innovation Ltd, Senior plc, and PayPoint plc. Previously Giles was the Group Finance Director and Chief Financial Officer of Amersham plc, acquired by GE Healthcare in 2004, and previously served as Director of Victrex plc. Prior to his role at Amersham, he was a partner with Arthur Andersen in the UK. He is a graduate of the University of York.
Ian Much joined BTG as a non-executive director in August 2010. He is Chairman of the Remuneration Committee and a member of the Audit and Nominations Committees.
Ian was Chief Executive of De La Rue plc between 1998 and 2004 and Chief Executive of T&N plc between 1996 and 1998. Previous non-executive director appointments include Manchester United plc, Camelot plc, Admiral plc, and Chemring Group plc.
Jim O’Shea joined BTG as a non-executive director in April 2009 and he is a member of the Nomination Committee.
He is the Chairman of Cardiome Pharma, a director of Prostrakan Group Plc, Trevi Therapeutics, Inc., and Ocular Therapeutix™, and a former Chairman of the US National Pharmaceuticals Council. From 2007 to 2008, he was Vice Chairman of Sepracor, Inc., where he was also President and Chief Operating Officer from 1999 to 2007. Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals (US), a business unit of Zeneca Inc. While at Zeneca, he held several management positions of increasing responsibility in international sales and marketing in the US and the UK.
Richard Wohanka joined BTG as a non-executive director in January 2013 and is a member of the Audit Committee.
Richard has more than twenty years' experience in building asset management businesses. He was CEO of Union Bancaire Privée Asset Management between October 2009 and June 2012, and from 2001 to 2009 he was CEO of Fortis Investment Management. Richard is a board member of the Nuclear Liabilities Fund and of Scottish Widows.
We have a rich heritage spanning many decades, from our commercialisation of intellectual property to our transformation into a specialist healthcare company.Read more
Our Code of Conduct has been developed to promote ethical behaviour from all our employees and is based on our foundation of core company values.Read more